Annovis Bio, Inc.(ANVS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ANVS Annovis Bio, Inc.

Trading 07-05 12:40:47 EDT

10.44

+2.36

+29.21%

High11.46	Low7.69	Vol12.65M
Open7.69	D1 Closing8.08	Amplitude46.66%
Mkt Cap116.63M	Tradable Cap87.19M	Total Shares11.17M
T/O128.38M	T/O Rate151.47%	Tradable Shares8.35M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"ANVS","market":"US","secType":"STK","nameCN":"Annovis Bio, Inc.","latestPrice":10.4399,"timestamp":1720197640295,"preClose":8.08,"halted":0,"volume":12650060,"delay":0,"floatShares":8351723,"shares":11171480,"eps":-5.629721,"marketStatus":"Trading","change":2.3599,"latestTime":"07-05 12:40:47 EDT","open":7.69,"high":11.46,"low":7.69,"amount":128379677.86258,"amplitude":0.466584,"askPrice":10.59,"askSize":300,"bidPrice":10.37,"bidSize":6,"shortable":0,"etf":0,"ttmEps":-5.629721,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1720209600000},"marketStatusCode":2,"adr":0,"listingDate":1580274000000,"exchange":"NYSE","adjPreClose":8.08,"preHourTrading":{"tag":"盘前","latestPrice":7.691,"preClose":8.08,"latestTime":"09:29 EDT","volume":31986,"amount":242205.4671282,"timestamp":1720186164415},"postHourTrading":{"tag":"盘后","latestPrice":7.85,"preClose":8.08,"latestTime":"16:59 EDT","volume":83433,"amount":657369.1652,"timestamp":1720040366878},"volumeRatio":2.759019,"impliedVol":1.8523,"impliedVolPercentile":0.049},"requestUrl":"/m/hq/s/ANVS","defaultTab":"news","newsList":[{"id":"2448481834","title":"Annovis (ANVS) Up as Its Lead Candidate Meets Goals in PD Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2448481834","media":"Zacks","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2448481834?lang=en_us&edition=fundamental","pubTime":"2024-07-03 21:10","pubTimestamp":1720012200,"startTime":"0","endTime":"0","summary":"Annovis BioANVS announced that it has met the primary and secondary endpoints in the late-stage study evaluating two dosage strengths  of its lead product candidate, buntanetap,for treating Parkinson’s disease . Per the company, treatment with the candidate demonstrated a safe and effective improvement in motor and non-motor activities and improved cognitive functions in patients with early PD.Annovis’ shares surged 76.1% on Jul 2 following the encouraging news. Buntanetap, an orally available small molecule, has a unique mechanism of action that allows the candidate to reverse neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein and TDP43.In the same press release, Annovis clarified that although MDS-UPDRS Part II+III was initially chosen as the primary endpoint of the phase III PD study, MDS-UPDRS Part II alone was later deemed more appropriate for reflecting clinically relevant changes, based on FDA feedback. The","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/huDYWWooSs3LEZkYeanM9w--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/c9aff063e0b66455eb97289290f920eb","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/huDYWWooSs3LEZkYeanM9w--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/c9aff063e0b66455eb97289290f920eb"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/annovis-anvs-lead-candidate-meets-131000991.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1169590202.USD","BK4139","BK4023","PD","BK4505","ALXO","CGEN","LU1169589451.USD","ALGS","BK4121","ANVS"],"gpt_icon":0},{"id":"2448119040","title":"Market Today: Paramount Eyes BET Sale, Tesla Surges on Deliveries, Medtronic Ends Slump","url":"https://stock-news.laohu8.com/highlight/detail?id=2448119040","media":"GuruFocus","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2448119040?lang=en_us&edition=fundamental","pubTime":"2024-07-03 05:32","pubTimestamp":1719955920,"startTime":"0","endTime":"0","summary":"Market Performance The stock market ended the session on an upbeat note. The major indices all closed near their highs of the day, with the S&P 500 above 5,500 for the first time and the Nasdaq Compos","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gurufocus.com/news/2467835/market-today-paramount-eyes-bet-sale-tesla-surges-on-deliveries-medtronic-ends-slump","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gurufocus_highlight","symbols":["IE0004445015.USD","BK4516","AMZN","OEF","BK4566","IE00BJJMRY28.SGD","BK4559","LU2505996681.GBP","ANVS","AAPL","LU2592432038.USD","BK4194","LU0056508442.USD","PGRE","LU0127658192.USD","LU0385154629.USD","SPXU","SSO","MSFT","TPX","TSLA","UPRO",".SPX","VOO","LU1363072403.SGD","BK4550","ESmain","COST","BK4567","OEX","BIRK","BK4139","LU2095319765.USD","LU2210149790.SGD","SH","LU1066053197.SGD","SDS","IVV","LU2461242641.AUD","LU0971096721.USD","LU2210150020.SGD","BK4097","LU0943347566.SGD","TSLL","EW","SPY","ACGL","WMT","LU2505996509.AUD","BK4528","BK4146","IE00BDCRKT87.USD"],"gpt_icon":0},{"id":"2448193320","title":"Annovis Bio Shares Up Sharply on Positive Parkinson's Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2448193320","media":"Dow Jones","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2448193320?lang=en_us&edition=fundamental","pubTime":"2024-07-03 02:49","pubTimestamp":1719946140,"startTime":"0","endTime":"0","summary":"Annovis Bio's shares rose sharply as new data from a phase III study showed buntanetap is safe and effective in patients with early Parkinson's disease at improving motor and non-motor activities as well as cognitive functions.The stock is trading up 97%, at $10.39, after closing the previous day's session at $5.27. Annovis is on track for its best performance in three years but is still down more than 40% in the year to date.The Malvern, Pa.-based clinical-stage biotechnology company said buntanetap, a drug in development for the treatment of neurodegenerative diseases, showed dose-dependent and statistically significant improvements in cognition in the overall enrolled Parkinson's population.Parkinson's patients with substantial cognitive decline exhibited a very pronounced improvement and buntanetap's activity resulted in statistically significant improvements in all primary and secondary endpoints, Annovis Bio said.\"These compelling data reinforce our commitment to advancing buntan","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANVS"],"gpt_icon":0},{"id":"2448199737","title":"Annovis doubles as lead drug improves Parkinson’s","url":"https://stock-news.laohu8.com/highlight/detail?id=2448199737","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2448199737?lang=en_us&edition=fundamental","pubTime":"2024-07-03 02:30","pubTimestamp":1719945051,"startTime":"0","endTime":"0","summary":"Shares of Annovis Bio  more than doubled in value on Tuesday after the company said its lead asset, buntanetap, was found to be safe and effective in improving the physical and cognitive functions of patients with early Parkinson’s disease. Updating data from its Phase 3 PD trial, Annovis  said buntanetap, designed to target neurotoxic proteins, maintained cognition in the entire patient population at 10 and 20 mg doses, while those on placebo deteriorated throughout the study. At 20 mg, the study drug “showed significant improvement in cognition compared to placebo,” the company added. With a consistent tolerability profile across early and advanced PD patients, buntanetap led to statistically significant improvements in all primary and secondary endpoints in specific subgroups, according to Annovis Bio . The company has scheduled a webcast at 4:30 PM ET on July 2 to discuss additional results.","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1038411882/image_1038411882.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1038411882/image_1038411882.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4121821-annovis-stock-jumps-data-parkinsons-drug","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["ANVS","BK4139"],"gpt_icon":0},{"id":"2448603391","title":"Annovis Bio's stock rockets 119% after reporting positive data in Parkinson's disease trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2448603391","media":"Dow Jones","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2448603391?lang=en_us&edition=fundamental","pubTime":"2024-07-03 01:57","pubTimestamp":1719943020,"startTime":"0","endTime":"0","summary":"Stock on track for its best one-day performance in three years. Annovis Bio Inc.'s stock rocketed 119% on Tuesday after the biotech reported positive results in a late-stage trial of its Parkinson's disease treatment called buntanetap.The stock was on track for its best performance since May 21, 2021, when it gained 127%.\"We are very pleased to see improvements in many of our patients over such a short course of treatment. These compelling data reinforce our commitment to advancing buntanetap into a longer study, which will allow us not only to verify observed symptomatic improvements but also to explore buntanetap's disease-modifying properties,\" Maria Maccecchini, the founder, president and CEO of Annovis Bio, said in prepared remarks.Treatment with 20 mg \"showed significant improvement in cognition compared with placebo,\" the company said.\"Buntanetap maintained a consistent safety profile across all participants, with no significant differences between early and advanced PD patients","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ANVS"],"gpt_icon":0},{"id":"2448164297","title":"Annovis Bio Price Target Maintained With a $67.00/Share by Rodman & Renshaw","url":"https://stock-news.laohu8.com/highlight/detail?id=2448164297","media":"Dow Jones","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2448164297?lang=en_us&edition=fundamental","pubTime":"2024-07-03 00:57","pubTimestamp":1719939420,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ANVS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 02, 2024 12:57 ET (16:57 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANVS"],"gpt_icon":0},{"id":"2448504164","title":"Annovis Shares Rise After Study Shows Effectiveness of Parkinson's Treatment Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2448504164","media":"MT Newswires Live","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2448504164?lang=en_us&edition=fundamental","pubTime":"2024-07-03 00:43","pubTimestamp":1719938621,"startTime":"0","endTime":"0","summary":"Annovis Bio  shares surged 25% in recent trading Tuesday after an advance study showed buntanetap was effective in improving motor, non-motor and cognitive functions in patients with early Parkinson's disease.Buntanetap halted cognitive decline in all enrolled patients, while patients with mild dementia showed improved cognition, the company said.Annovis said the drug showed improvement in motor and non-motor functions in patients diagnosed with Parkinson's disease more than three years and patients with postural instability and gait difficulty.Results from the study show that buntanetap met both primary and secondary endpoints in specified subgroups.Price: 6.57, Change: +1.30, Percent Change: +24.67","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","ANVS"],"gpt_icon":0},{"id":"2448158419","title":"Annovis Bio Announces New Data from Phase III Parkinson’s Study Highlighting Improvements in Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and Cognition after Treatment with Buntanetap","url":"https://stock-news.laohu8.com/highlight/detail?id=2448158419","media":"GlobeNewswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2448158419?lang=en_us&edition=fundamental","pubTime":"2024-07-02 20:00","pubTimestamp":1719921600,"startTime":"0","endTime":"0","summary":"Changes in MMSE after treatment with 10mg or 20mg buntanetap compared to baseline and placebo. Changes in MDS-UPDRS after treatment with 10mg or 20mg buntanetap in patients with a PD diagnosis over 3 years compared to baseline and placebo. Changes in MDS-UPDRS after treatment with 10mg or 20mg buntanetap in patients with PIGD","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/07/02/2907365/0/en/Annovis-Bio-Announces-New-Data-from-Phase-III-Parkinson-s-Study-Highlighting-Improvements-in-Unified-Parkinson-s-Disease-Rating-Scale-MDS-UPDRS-and-Cognition-after-Treatment-with-B.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["III","ANVS"],"gpt_icon":0},{"id":"2448991980","title":"Apellis (APLS) Falls on Second Negative CHMP Opinion for GA Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2448991980","media":"Zacks","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2448991980?lang=en_us&edition=fundamental","pubTime":"2024-07-01 20:44","pubTimestamp":1719837840,"startTime":"0","endTime":"0","summary":"Apellis plans to request a re-examination of the opinion and anticipates a final decision in the fourth quarter of 2024. The negative opinion followed an Ad Hoc Expert Group meeting, where experts agreed that the size of GA lesions is an acceptable primary outcome measure for GA studies and that microperimetry is the best available functional measure for GA.The company’s shares lost 7.6% following the news on Jun 28. Apellis is currently gearing up to promptly initiate the re-examination process to clinch a nod for the GA treatment in the EU by the year’s end.The drug has witnessed robust initial uptake since its commercial launch in March 2023.Syfovre recorded sales of $137.5 million in the first quarter of 2024, which increased 20.3% sequentially, owing to continued strong demand, thereby driving revenues for the company. Apellis delivered more than 72,000 commercial vials and nearly 5,000 samples of Syfovre to doctors in the first quarter. As of Mar 31, 2024, the total number of dru","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/vtsVt8PEmb10KQ4cnwEJfQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/96776645e0ac7ab203b7d5e3b37251a6","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/vtsVt8PEmb10KQ4cnwEJfQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/96776645e0ac7ab203b7d5e3b37251a6"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/apellis-apls-falls-second-negative-124400722.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4215","LU1093756168.USD","BK4139","BK4505","BK4585","CHMP","BK4588","BK4121","CGEN","ANVS","MAA","LU1093756325.SGD","APLS","BK4087","ALXO"],"gpt_icon":0},{"id":"2448291811","title":"PTC Therapeutics (PTCT) Down on Negative CHMP Opinion on DMD Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2448291811","media":"Zacks","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2448291811?lang=en_us&edition=fundamental","pubTime":"2024-07-01 20:00","pubTimestamp":1719835200,"startTime":"0","endTime":"0","summary":"PTC TherapeuticsPTCT announced that the Committee for Medicinal Products for Human Use  of the European Commission  once again adopted a negative opinion on the annual renewal of the conditional marketing authorization of Translarna  to treat nonsense mutation Duchenne muscular dystrophy .PTC Therapeutics plans to further request a re-examination of the negative opinion regarding Translarna in the EU. Meanwhile, the marketing authorization for Translarna will remain in effect until the re-examination procedure is completed and the EC announces its decision. Given the expected timeline for these procedures, PTCT anticipates that Translarna will remain available for boys and young men with nmDMD through the end of 2024, even if the negative opinion is ultimately upheld and ratified.Please note that the CHMP had previously issued a negative opinion in January 2024 regarding the continued marketing approval of Translarna for the nmDMD indication. However, in May 2024, the EC decided agains","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/TnZya4zmXcZQTiM85rn8xg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/955c0f2ed0992898cedf76a9efa5b1f2","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/TnZya4zmXcZQTiM85rn8xg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/955c0f2ed0992898cedf76a9efa5b1f2"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ptc-therapeutics-ptct-down-negative-120000629.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PTC","EC","BK4576","CHMP","BK4121","CGEN","BK4201","ANVS","LU1923623000.USD","BK4087","LU1951198990.SGD","BK4588","LU0109394709.USD","BK4023","PTCT","BK4585","LU1951200564.SGD","BK4139","ALXO","BK4554","LU0320765992.SGD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2447601591","title":"Annovis: Strong Sell Reiteration Prior To Phase 3 Data In Parkinson's Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2447601591","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2447601591?lang=en_us&edition=fundamental","pubTime":"2024-06-30 23:48","pubTimestamp":1719762505,"startTime":"0","endTime":"0","summary":"Annovis Bio's only potential catalyst is the upcoming Phase 3 readout for Parkinson's disease.The company's changes to the primary endpoints of that trial, contrary to the FDA's wishes, cause concern.","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/551986071/image_551986071.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/551986071/image_551986071.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4701729-annovis-strong-sell-reiteration-prior-to-phase-3-data-in-parkinsons-disease","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["LU0456855351.SGD","LU2468319806.SGD","PD","LU1023059063.AUD","LU0672654240.SGD","GB00BDT5M118.USD","IE00B19Z9P08.USD","LU2237438978.USD","BK4588","IE00B19Z9Z06.USD","BK4532","BK4139","LU0640476718.USD","LLY","LU0234570918.USD","LU1814569148.SGD","LU0708995401.HKD","IE00BJJMRZ35.SGD","LU0238689110.USD","IE00B2B36J28.USD","LU0122379950.USD","BK4581","LU0198837287.USD","IE00B1BXHZ80.USD","LU0417517546.SGD","LU1988902786.USD","LU1267930730.SGD","LU1551013425.SGD","BK4007","LU0061475181.USD","LU0289739699.SGD","BK4534","LU1169589451.USD","LU0058720904.USD","BIIB","IE00B894F039.SGD","LU0320765992.SGD","LU2264538146.SGD","LU0320765059.SGD","LU1057294990.SGD","BK4533","LU0471298777.SGD","LU0256863811.USD","LU1280957306.USD","BK4023","LU0109391861.USD","IE00BJT1NW94.SGD","ANVS","LU0882574055.USD","IE0004445239.USD"],"gpt_icon":0},{"id":"2446500351","title":"Merck's (MRK) New Pneumococcal Jab Capvaxive Gets CDC Panel Vote","url":"https://stock-news.laohu8.com/highlight/detail?id=2446500351","media":"Zacks","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2446500351?lang=en_us&edition=fundamental","pubTime":"2024-06-28 19:28","pubTimestamp":1719574080,"startTime":"0","endTime":"0","summary":"Merck MRK announced that the U.S. Centers for Disease Control and Prevention’s  Advisory Committee on Immunization Practices  has unanimously voted to recommend MRK’s newly approved 21-valentpneumococcal conjugate vaccine  Capvaxive. The FDA approved Capvaxive earlier this month for the prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults. Capvaxive became the first PCV specifically designed for adults to be approved by the FDA.Capvaxive targets serotypes that account for approximately 84% of all invasive pneumococcal disease in older adults  in the United States, including eight serotypes not covered by currently licensed vaccines.The final patient population for whom ACIP recommends Merck’s Capvaxive are adults aged 19 years and older who have begun their pneumococcal vaccine series with 13-valent PCV  but have not received all the recommended pneumococcal 23-valent polysaccharide  vaccine doses.Additionally, the ACIP advises that shared clinical decision-","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/sWuU5JHrorQjYnKhObHttQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1b28b8f55ab25205feceb1a2771a2b3a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/sWuU5JHrorQjYnKhObHttQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1b28b8f55ab25205feceb1a2771a2b3a"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mercks-mrk-pneumococcal-jab-capvaxive-112800179.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0965509010.AUD","LU0211331839.USD","CDC","ALXO","LU1066053197.SGD","BK4585","SG9999001176.SGD","ANVS","LU0122379950.USD","BK4533","LU0208291251.USD","SG9999002232.USD","LU1989772840.SGD","LU0985320562.USD","BK4534","SG9999001440.SGD","LU2023250504.SGD","LU2106854487.HKD","LU1989772923.USD","SG9999013999.USD","SG9999014542.SGD","BK4588","CGEN","IE0002141913.USD","IE0009355771.USD","LU0965509101.SGD","IE00BSNM7G36.USD","IE00B2B36J28.USD","BK4516","IE00BBT3K403.USD","LU1917777945.USD","LU2461242641.AUD","LU1989771016.USD","MRK","IE00BFTCPJ56.SGD","LU1023059063.AUD","BK4121","LU0289739699.SGD","LU1093756168.USD","SG9999014567.USD","IE00B1BXHZ80.USD","LU0070302665.USD","LU1430594728.SGD","LU2361044949.HKD","IE00BLSP4239.USD","LU2023250843.SGD","LU1291159041.SGD","LU0234572021.USD","LU0320765489.SGD","LU2361045086.USD"],"gpt_icon":0},{"id":"2446576475","title":"Dr. Reddy's (RDY) to Acquire Haleon's Nicotine Addiction Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2446576475","media":"Zacks","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2446576475?lang=en_us&edition=fundamental","pubTime":"2024-06-27 22:25","pubTimestamp":1719498300,"startTime":"0","endTime":"0","summary":"Dr. Reddy’s LaboratoriesRDY has announced a definitive agreement with Haleon plc HLN to acquire its global portfolio of consumer healthcare brands in the Nicotine Replacement Therapy  category, excluding the United States.The strategic move is set to further strengthen Dr. Reddy’s OTC business. Please note that Haleon’s Nicotinell is the world's second-largest brand in the NRT category, excluding the United States. It holds either the first or second position in 14 out of the top 17 global markets, with its lozenge/mini lozenge format being the top choice globally. Additionally, Nicotinell is among the top 15 OTC brands in Europe  and ranks 32nd among all OTC brands globally . In 2023, Nicotinell generated approximately GBP 217 million in revenues.Please note that NRT is recommended by the WHO's Model List of Essential Medicines for treating nicotine use disorders. NRT also played a crucial role in the WHO's Access Initiative for Quitting Tobacco, whi","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/VTpWEp9iphTX3xsYcMogbg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ca9d72216d7bb42fc496430c3df29b41","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/VTpWEp9iphTX3xsYcMogbg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ca9d72216d7bb42fc496430c3df29b41"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dr-reddys-rdy-acquire-haleons-142500542.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ALXO","NRT","BK4523","BK4007","HLN","BK4532","RDY","BK4557","ANVS","BK4213","BK4183"],"gpt_icon":0},{"id":"2446550458","title":"Novo Nordisk's (NVO) Hypertension Drug Study Fails to Meet Goal","url":"https://stock-news.laohu8.com/highlight/detail?id=2446550458","media":"Zacks","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2446550458?lang=en_us&edition=fundamental","pubTime":"2024-06-27 22:22","pubTimestamp":1719498120,"startTime":"0","endTime":"0","summary":"Novo NordiskNVO lost 2.2% on Jun 26 after the company announced the failure of a late-stage study evaluating ocedurenoneto treat patients with uncontrolled hypertension and advanced chronic kidney disease . Consequently, the company said that it will recognize an impairment loss of around DKK 5.7 billion related to the intangible assets in the second quarter of 2024.Such recognition is expected to negatively impact operating profit growth by around 6 percentage points at the constant exchange rate  in 2024. This adjustment revises the previously stated operating profit outlook of 22% to 30% growth at CER, as communicated in their financial report for the first quarter of 2024.Novo Nordisk is slated to announce its financial results for the first six months of 2024 and update its financial outlook for 2024 on Aug 7, 2024.Based on interim analysis, an independent data monitoring determined that the study did not meet its primary endpoint of reducing systolic blood pressure from baseline.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/EaYjwqFOUx_QJeP7FQN8Aw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/723b414aa10600faf58f7a232ec73364","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/EaYjwqFOUx_QJeP7FQN8Aw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/723b414aa10600faf58f7a232ec73364"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/novo-nordisks-nvo-hypertension-drug-142200318.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ANVS","CGEN","NVO","IE00BZ1G4Q59.USD","BK4585","BK4007","BK4139","BK4121","ALXO","BK4588","BK4532","IE00BKVL7J92.USD"],"gpt_icon":0},{"id":"2446066554","title":"CASI Pharmaceuticals (CASI) Up on Buyout Offer for China Business","url":"https://stock-news.laohu8.com/highlight/detail?id=2446066554","media":"Zacks","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2446066554?lang=en_us&edition=fundamental","pubTime":"2024-06-27 21:42","pubTimestamp":1719495720,"startTime":"0","endTime":"0","summary":"CASI Pharmaceuticals, Inc. CASI announced that its board of directors has received a proposal from the chairman of the company for acquiring its business operations in China. Shares of this biopharmaceutical company are soaring in pre-market trading on the news.CASI Pharmaceuticals is focused on developing and commercializing innovative drugs in China, the United States, and the rest of the world.Dr. Wei-Wu He, CASI’s chairman of the board and CEO, sent a preliminary non-binding proposal letter, dated Jun 21, 2024, to the company for acquiring its business in China. He also made a proposal to acquire CASI’s all license-in, distribution and related rights in Asia  related to its pipeline products, including but not limited to Evomela, Folotyn, Cnct19, Bi-1206, Cb-5339, Cid-103 And Thiotepa, for $40.0 million.The purchase price includes an assumption of up to $20.0 million of debt.Subsequently, the board has formed a special committee, comprised solely of incumbent independent directors,","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/7zIelLdHLRtVfLSfNT5rgw--~B/aD01OTE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9210701387ebf346091e3459e7ff01de","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/7zIelLdHLRtVfLSfNT5rgw--~B/aD01OTE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9210701387ebf346091e3459e7ff01de"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/casi-pharmaceuticals-casi-buyout-offer-134200254.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CGEN","BK4588","BK4139","BK4006","AMR","BK4121","ANVS","CASI","ALXO","BK4585"],"gpt_icon":0},{"id":"2446534214","title":"Annovis Bio files patent for new manufacturing process of buntanetap","url":"https://stock-news.laohu8.com/highlight/detail?id=2446534214","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2446534214?lang=en_us&edition=fundamental","pubTime":"2024-06-27 20:39","pubTimestamp":1719491960,"startTime":"0","endTime":"0","summary":"Annovis Bio  Thursday announced the filing of a provisional patent covering the manufacturing process of new solid forms of buntanetap. This patent encompasses the methods for manufacturing the new crystalline form of buntanetap, which has demonstrated exceptional stability and efficacy. The patent also covers the entire synthesis process, from basic starting materials to finished  GMP product, suitable for manufacturing scale at ton quantities, Annovis Bio  said. The CMC protocol was submitted to the FDA and will be discussed in July, with the goal of continuing development of our drug and filing the NDA with the new crystal form. ANVS +0.35% premarket to $5.75. Source: Press Release","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/174697479/image_174697479.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/174697479/image_174697479.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4120008-annovis-bio-files-patent-for-new-manufacturing-process-of-buntanetap","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4139","ANVS"],"gpt_icon":0},{"id":"2446189093","title":"ImmunityBio (IBRX) Gains 17% in the Past Week: Here's Why","url":"https://stock-news.laohu8.com/highlight/detail?id=2446189093","media":"Zacks","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2446189093?lang=en_us&edition=fundamental","pubTime":"2024-06-26 21:41","pubTimestamp":1719409260,"startTime":"0","endTime":"0","summary":"ImmunityBio’s IBRX commercial portfolio comprises its only marketed drug, Anktiva .Anktiva, in combination with Bacillus Calmette-Guérin , got FDA approval in April 2024 for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer  with carcinoma in situ , with or without papillary tumors.ImmunityBio’s shares gained 16.7% in the past week following the announcement of insurance coverage for its drug across multiple states. Several healthcare plans now provide reimbursement for Anktiva, increasing patient access. Additionally, within just eight weeks since approval, several NMIBC CIS patients across the United States have already been treated with the immunotherapy.Initial sales figures for the Anktiva/BCG immunotherapy are expected to be reported in ImmunityBio’s second-quarter earnings release in July or August.Anktiva offers a significant advantage in its administration, as it can be administered by urologists in their offices and clinics without the need fo","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/sb.6qRd7FfGt7.wCjWz2vw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/675c0ae70cb5036ad2ceb9062f13afc2","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/sb.6qRd7FfGt7.wCjWz2vw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/675c0ae70cb5036ad2ceb9062f13afc2"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immunitybio-ibrx-gains-17-past-134100075.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ANVS","CGEN","BCG","IBRX","BK4139","BK4121","BK4135","ALXO"],"gpt_icon":0},{"id":"2446362785","title":"BRIEF-Annovis Bio Files Patent For New Composition Of Matter For Buntanetap","url":"https://stock-news.laohu8.com/highlight/detail?id=2446362785","media":"Reuters","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2446362785?lang=en_us&edition=fundamental","pubTime":"2024-06-26 20:13","pubTimestamp":1719403993,"startTime":"0","endTime":"0","summary":"June 26 (Reuters) - Annovis Bio Inc   :   * ANNOVIS BIO INC: FILES PATENT FOR NEW COMPOSITION OF MATTER FOR BUNTANETAPSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ANVS"],"gpt_icon":0},{"id":"2446362817","title":"Annovis Bio Files Patent for New Composition of Matter for Buntanetap","url":"https://stock-news.laohu8.com/highlight/detail?id=2446362817","media":"GlobeNewswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2446362817?lang=en_us&edition=fundamental","pubTime":"2024-06-26 20:00","pubTimestamp":1719403200,"startTime":"0","endTime":"0","summary":"MALVERN, Pa., June  26, 2024  (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/06/26/2904442/0/en/Annovis-Bio-Files-Patent-for-New-Composition-of-Matter-for-Buntanetap.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","IE00BYTNYM70.SGD","LU1102505762.USD","BK4585","BK4548","SG9999004220.SGD","IE00B0JY6M65.USD","ANVS","BK4023","IBN","LU1169589451.USD","BK4207","IE00B7N09G41.SGD","PD","BK4523","BK4139","LU1169590202.USD","BK4588","LU0066902890.USD","LU0251143458.SGD"],"gpt_icon":0},{"id":"2446282640","title":"Novo Nordisk (NVO) to Invest $4.1B in Clayton Facility Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2446282640","media":"Zacks","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2446282640?lang=en_us&edition=fundamental","pubTime":"2024-06-25 22:22","pubTimestamp":1719325320,"startTime":"0","endTime":"0","summary":"Novo NordiskNVO recently announced plans to make a significant investment of $4.1 billion  to construct a second fill and finishing manufacturing facility in Clayton, NC. This new facility aims to enhance the company's capacity to produce injectable treatments for patients with obesity and other chronic diseases. This expansion underscores NVO's commitment to addressing the growing global demand for its medical products.The investment represents one of the largest manufacturing expansions in Novo Nordisk's history. The new facility will add 1.4 million square feet of production space dedicated to aseptic manufacturing and finished product processes. This will effectively double the total square footage of all three ofits current facilities in North Carolina. The significant scale of this expansion highlights the company's strategic efforts to strengthen its manufacturing capabilities in a key location.Year to date, shares of Novo Nordisk have jumped 37.6% against the industry’s 20.9% d","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/EaYjwqFOUx_QJeP7FQN8Aw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/723b414aa10600faf58f7a232ec73364","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/EaYjwqFOUx_QJeP7FQN8Aw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/723b414aa10600faf58f7a232ec73364"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/novo-nordisk-nvo-invest-4-142200238.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1712237335.SGD","LU1623119135.USD","LU0820561909.HKD","LU0471298777.SGD","LLY","GB00BDT5M118.USD","LU0689472784.USD","LU2491049909.HKD","LU0417517546.SGD","LU0882574055.USD","LU0943347566.SGD","LU1804176565.USD","LU0079474960.USD","LU2237443549.SGD","IE00BFTCPJ56.SGD","ANVS","LU0672654240.SGD","LU0198837287.USD","BK4585","LU0820561818.USD","LU0320765059.SGD","ALXO","BK4533","LU2237438978.USD","LU1551013342.USD","NVO","IE00BKVL7J92.USD","LU2237443622.USD","BK4534","LU0114720955.EUR","LU1064131342.USD","IE00BZ1G4Q59.USD","BK4007","LU0640476718.USD","LU0456855351.SGD","LU2491050071.SGD","BK4532","LU2237443978.SGD","IE0002141913.USD","IE00B2B36J28.USD","LU1551013425.SGD","LU0097036916.USD","LU2265009873.SGD","LU0882574139.USD","LU1267930730.SGD","LU2237443382.USD","LU0466842654.USD","IE0009355771.USD","LU0238689110.USD","LU0385154629.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.annovisbio.com","stockEarnings":[{"period":"1week","weight":0.4101},{"period":"1month","weight":0.1865},{"period":"3month","weight":-0.2681},{"period":"6month","weight":-0.3404},{"period":"1year","weight":-0.4276},{"period":"ytd","weight":-0.5679}],"compareEarnings":[{"period":"1week","weight":0.0109},{"period":"1month","weight":0.0448},{"period":"3month","weight":0.0748},{"period":"6month","weight":0.1785},{"period":"1year","weight":0.2426},{"period":"ytd","weight":0.1602}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which is in Phase 3 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.001878},{"month":2,"riseRate":0.4,"avgChangeRate":0.208855},{"month":3,"riseRate":0.4,"avgChangeRate":-0.008916},{"month":4,"riseRate":0.2,"avgChangeRate":-0.160489},{"month":5,"riseRate":0.6,"avgChangeRate":0.247553},{"month":6,"riseRate":0.6,"avgChangeRate":0.216567},{"month":7,"riseRate":0.6,"avgChangeRate":0.023509},{"month":8,"riseRate":0.5,"avgChangeRate":-0.04425},{"month":9,"riseRate":0.5,"avgChangeRate":-0.049932},{"month":10,"riseRate":0,"avgChangeRate":-0.151029},{"month":11,"riseRate":0.75,"avgChangeRate":0.114437},{"month":12,"riseRate":0.5,"avgChangeRate":0.329002}],"exchange":"NYSE","name":"Annovis Bio, Inc.","nameEN":"Annovis Bio, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Annovis Bio, Inc.(ANVS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Annovis Bio, Inc.(ANVS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Annovis Bio, Inc.,ANVS,Annovis Bio, Inc.股票,Annovis Bio, Inc.股票老虎,Annovis Bio, Inc.股票老虎国际,Annovis Bio, Inc.行情,Annovis Bio, Inc.股票行情,Annovis Bio, Inc.股价,Annovis Bio, Inc.股市,Annovis Bio, Inc.股票价格,Annovis Bio, Inc.股票交易,Annovis Bio, Inc.股票购买,Annovis Bio, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Annovis Bio, Inc.(ANVS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Annovis Bio, Inc.(ANVS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction